An Update on Adverse Outcome Pathways Leading to Liver Injury

Overview

Journal Appl In Vitro Toxicol

Date 2019 Mar 29

PMID 30918914

Citations 8

Authors

Eva Gijbels

Mathieu Vinken

Affiliations

Soon will be listed here.

Abstract

Chemical-induced liver injury can be manifested in a number of ways, such as cholestasis, steatosis, fibrosis, and cancer. The mechanisms driving these toxicological processes have been well characterized and have been embedded in adverse outcome pathway frameworks in recent years. This article provides a concise overview of these constructs.

Citing Articles

Hybrid non-animal modeling: A mechanistic approach to predict chemical hepatotoxicity.

Chung E, Wen X, Jia X, Ciallella H, Aleksunes L, Zhu H J Hazard Mater. 2024; 471():134297.

PMID: 38677119 PMC: 11519847. DOI: 10.1016/j.jhazmat.2024.134297.

New Approach Methods for Hazard Identification: A Case Study with Azole Fungicides Affecting Molecular Targets Associated with the Adverse Outcome Pathway for Cholestasis.

Knebel C, Sussmuth R, Hammer H, Braeuning A, Marx-Stoelting P Cells. 2022; 11(20).

PMID: 36291160 PMC: 9600068. DOI: 10.3390/cells11203293.

Mechanism-driven modeling of chemical hepatotoxicity using structural alerts and an in vitro screening assay.

Jia X, Wen X, Russo D, Aleksunes L, Zhu H J Hazard Mater. 2022; 436:129193.

PMID: 35739723 PMC: 9262097. DOI: 10.1016/j.jhazmat.2022.129193.

approaches in organ toxicity hazard assessment: current status and future needs in predicting liver toxicity.

Bassan A, Alves V, Amberg A, Anger L, Auerbach S, Beilke L Comput Toxicol. 2022; 20.

PMID: 35340402 PMC: 8955833. DOI: 10.1016/j.comtox.2021.100187.

Adverse Outcome Pathways as Versatile Tools in Liver Toxicity Testing.

Arnesdotter E, Gijbels E, Dos Santos Rodrigues B, Vilas-Boas V, Vinken M Methods Mol Biol. 2022; 2425:521-535.

PMID: 35188645 DOI: 10.1007/978-1-0716-1960-5_20.

References

Schoemaker M, Conde de la Rosa L, Buist-Homan M, Vrenken T, Havinga R, Poelstra K . Tauroursodeoxycholic acid protects rat hepatocytes from bile acid-induced apoptosis via activation of survival pathways. Hepatology. 2004; 39(6):1563-73. DOI: 10.1002/hep.20246. View

Zollner G, Trauner M . Molecular mechanisms of cholestasis. Wien Med Wochenschr. 2006; 156(13-14):380-5. DOI: 10.1007/s10354-006-0312-7. View

Zollner G, Trauner M . Mechanisms of cholestasis. Clin Liver Dis. 2008; 12(1):1-26, vii. DOI: 10.1016/j.cld.2007.11.010. View

Ozer J, Ratner M, Shaw M, Bailey W, Schomaker S . The current state of serum biomarkers of hepatotoxicity. Toxicology. 2008; 245(3):194-205. DOI: 10.1016/j.tox.2007.11.021. View

Friedman S . Mechanisms of hepatic fibrogenesis. Gastroenterology. 2008; 134(6):1655-69. PMC: 2888539. DOI: 10.1053/j.gastro.2008.03.003. View

Wagner M, Zollner G, Trauner M . New molecular insights into the mechanisms of cholestasis. J Hepatol. 2009; 51(3):565-80. DOI: 10.1016/j.jhep.2009.05.012. View

Friedman S . Evolving challenges in hepatic fibrosis. Nat Rev Gastroenterol Hepatol. 2010; 7(8):425-36. DOI: 10.1038/nrgastro.2010.97. View

Laverty H, Antoine D, Benson C, Chaponda M, Williams D, Park B . The potential of cytokines as safety biomarkers for drug-induced liver injury. Eur J Clin Pharmacol. 2010; 66(10):961-76. DOI: 10.1007/s00228-010-0862-x. View

Ankley G, Bennett R, Erickson R, Hoff D, Hornung M, Johnson R . Adverse outcome pathways: a conceptual framework to support ecotoxicology research and risk assessment. Environ Toxicol Chem. 2010; 29(3):730-41. DOI: 10.1002/etc.34. View

10.

Padda M, Sanchez M, Akhtar A, Boyer J . Drug-induced cholestasis. Hepatology. 2011; 53(4):1377-87. PMC: 3089004. DOI: 10.1002/hep.24229. View

11.

Lee U, Friedman S . Mechanisms of hepatic fibrogenesis. Best Pract Res Clin Gastroenterol. 2011; 25(2):195-206. PMC: 3079877. DOI: 10.1016/j.bpg.2011.02.005. View

12.

Vinken M, Pauwels M, Ates G, Vivier M, Vanhaecke T, Rogiers V . Screening of repeated dose toxicity data present in SCC(NF)P/SCCS safety evaluations of cosmetic ingredients. Arch Toxicol. 2011; 86(3):405-12. DOI: 10.1007/s00204-011-0769-z. View

13.

Woolbright B, Jaeschke H . Novel insight into mechanisms of cholestatic liver injury. World J Gastroenterol. 2012; 18(36):4985-93. PMC: 3460324. DOI: 10.3748/wjg.v18.i36.4985. View

14.

Vinken M, Maes M, Vanhaecke T, Rogiers V . Drug-induced liver injury: mechanisms, types and biomarkers. Curr Med Chem. 2013; 20(24):3011-21. DOI: 10.2174/0929867311320240006. View

15.

Lee W . Drug-induced acute liver failure. Clin Liver Dis. 2013; 17(4):575-86, viii. PMC: 3838908. DOI: 10.1016/j.cld.2013.07.001. View

16.

Villeneuve D, Crump D, Garcia-Reyero N, Hecker M, Hutchinson T, LaLone C . Adverse outcome pathway (AOP) development I: strategies and principles. Toxicol Sci. 2014; 142(2):312-20. PMC: 4318923. DOI: 10.1093/toxsci/kfu199. View

17.

Villeneuve D, Crump D, Garcia-Reyero N, Hecker M, Hutchinson T, LaLone C . Adverse outcome pathway development II: best practices. Toxicol Sci. 2014; 142(2):321-30. PMC: 4318924. DOI: 10.1093/toxsci/kfu200. View

18.

Van den Hof W, Ruiz-Aracama A, Van Summeren A, Jennen D, Gaj S, Coonen M . Integrating multiple omics to unravel mechanisms of Cyclosporin A induced hepatotoxicity in vitro. Toxicol In Vitro. 2015; 29(3):489-501. DOI: 10.1016/j.tiv.2014.12.016. View

19.

Mellor C, Steinmetz F, Cronin M . The identification of nuclear receptors associated with hepatic steatosis to develop and extend adverse outcome pathways. Crit Rev Toxicol. 2015; 46(2):138-52. DOI: 10.3109/10408444.2015.1089471. View

20.

Vinken M, Knapen D, Vergauwen L, Hengstler J, Angrish M, Whelan M . Adverse outcome pathways: a concise introduction for toxicologists. Arch Toxicol. 2017; 91(11):3697-3707. PMC: 5805086. DOI: 10.1007/s00204-017-2020-z. View